A slump in sales due to COVID-19, a significant reorientation of strategy in Japan, continued pressures over US investigations into price-fixing, a major biosimilars deal and a key new respiratory launch meant there was plenty to talk about during Teva’s presentation of its second-quarter results this week.
Teva Sees COVID Sales Correction
Takes Impairment On Japanese Venture And Bolsters Biosimilars Business
In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.
